

Supplementary Materials

Table S1 to S5

Figure S1 to S8

References for Supplementary Materials

In:

Frequent Detection of Infectious Xenotropic Murine Leukemia Virus (XMLV) in Human Cultures Established from Mouse Xenografts

Yu-An Zhang¹, Anirban Maitra², Jer-Tsong Hsieh³, Charles M. Rudin⁴, Craig D. Peacock⁴, Collins Karikari², Rolf A. Brekken¹, Victor Stastny¹, Boning Gao¹, Luc Girard¹, Ignacio Wistuba⁵, Eugene Frenkel⁶, John D. Minna¹ and Adi F. Gazdar^{1*}

¹ Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America,

² Departments of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America,

³ Department of Urology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America,

⁴ Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America,

⁵ Department of Pathology, MD Anderson Cancer Center, Houston, Texas, United States of America,

⁶ Division of Hematology-Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States of America

*Corresponding author at: UT Southwestern Medical Center, Bld NB8, 206, 6000 Harry Hines Blvd., Dallas, TX 75390-8593, USA. Tel.: +1 214 648 4921; fax: +1 214 648 4940.
E-mail address: adi.gazdar@utsouthwestern.edu (A.F. Gazdar).

Table S1. List of xenograft cell lines examined for murine leukemia virus detection				
Cell line type	Cell lines¹	Implants	Mice	Source: lab PI
NSCLC	H1703 xenograft	NCI-H1703 cells	SCID-NOD	R. Brekken
NSCLC	H1975 xenograft	NCI-H1975 cells	SCID-NOD	R. Brekken
NSCLC	H1993 xenograft	NCI-H1993 cells	SCID-NOD	R. Brekken
NSCLC	1065met	NCI-H1299 cells	nu/nu	B. Gao/J.Minna
NSCLC	LX7	Tumor	nu/nu	C. Rudin
NSCLC	LX14	Tumor	nu/nu	C. Rudin
NSCLC	LX31	Tumor	nu/nu	C. Rudin
SCLC	NCI-N417	Tumor	nu/nu	G. Bepler & A.Gazdar
SCLC	LX22	Tumor	nu/nu	C. Rudin
SCLC	LX33	Tumor	nu/nu	C. Rudin
SCLC	LX36	Tumor	nu/nu	C. Rudin
SCLC	LX44	Tumor	nu/nu	C. Rudin
SCLC	LX47	Tumor	nu/nu	C. Rudin
SCLC	LX48	Tumor	nu/nu	C. Rudin
Pancreas	PANC-1 xenograft	PANC-1 cells	nu/nu	R. Brekken
Pancreas	MIA PaCa-2 xenograft	MIA PaCa-2 cells	nu/nu	R. Brekken
Pancreas	XCL1	Tumor	nu/nu	A. Maitra
Pancreas	XCL2	Tumor	nu/nu	A. Maitra
Pancreas	XCL3	Tumor	nu/nu	A. Maitra
Pancreas	CAK1	Tumor	nu/nu	A. Maitra
Pancreas	Pa03C	Tumor	nu/nu	A. Maitra
Pancreas	Pa09C	Tumor	nu/nu	A. Maitra
Pancreas	Pa20C	Tumor	nu/nu	A. Maitra
Pancreas	Pa36C	Tumor	nu/nu	A. Maitra
Prostate	C4-2	LNCaP cells	nu/nu	JT Hsieh
Prostate	LAPC-4	Tumor	SCID	C. Sawyers & JT. Hsieh

1. The cell lines in bold were free of mouse DNA detection and positive for murine leukemia virus sequences. See Sup. References [1] for additional information on the pancreatic cell lines from A Maitra lab.

Table S2. List of non-xenograft cell lines examined for murine leukemia virus detection			
Cell line type (no. of total lines)	Positive cell lines¹	Negative cell lines	Source: Lab PI
NSCLC (49)	NCI-H1155	Calu3 PC9 NCI-H23 NCI-H522 NCI-H647 NCI-H650 NCI-H820 HCC827 NCI-H838 NCI-H920 HCC954 NCI-H969 DFC1024 DFC1032 NCI-H1264 NCI-1299 NCI-H1334 NCI-H1355 NCI-H1373 NCI-H1395 NCI-H1437 NCI- H1568 NCI-H1573 NCI-H1650 NCI-H1693 NCI-H1703 NCI-H1792 NCI- H1819 NCI-H1944 NCI-H1975 NCI-H1993 NCI-H2009 NCI-H2030 NCI- H2073 NCI-H2086 NCI-H2122 NCI-H2228 HCC2279 NCI-H2291 HCC2374 NCI-H2405 HCC2814 HCC2935 NCI-H3255 HCC4006 HCC4011 HCC4017 HCC4019	A.Gazdar
SCLC (54)	NCI-H60 NCI-H182 NCI-H289 NCI-H1092 NCI-H1514	HCC33 NCI-H69 NCI-H82 NCI-H128 NCI-H146 NCI-H187 NCI-H196 NCI- H209 NCI-H220 NCI-H345 NCI-H378 NCI-H510 NCI-H524 NCI-H526 NCI- H711 NCI-H738 NCI-H740 NCI-H748 NCI-H841 NCI-H865 NCI-H889 HCC970 NCI-H1045 NCI-H1048 NCI-H1105 NCI-1184 NCI-H1238 NCI- H1284 NCI-H1304 NCI-H1341 NCI-H1417 NCI-H1436 NCI-H1450 NCI- H1607 NCI-H1618 NCI-H1672 NCI-H1694 NCI-H1870 NCI-H1876 NCI- H1926 NCI-H1930 NCI-H1963 NCI-H1994 NCI-H2029 NCI-H2107 NCI- H2141 NCI-H2171 NCI-H2195 NCI-H2196	A.Gazdar
NSCLC (4)	NCI-H460	NCI-H358 H460TB10 H4606-05	C.Rudin
SCLC (4)	NCI-H82 NCI-H146	H82DS-06 H146CH-05	C.Rudin
Pancreas (9)		MIAPaCa-2 PANC-1 ASPC1 BXPC3 Panc8.13 Pa29C Pa21C Pa28C Pa16C	A.Maitra
Colon (1)	RKO²		A.Maitra
Pancreas (2)		MIAPaCa-2 PANC-1	R.Brekken
Prostate (7)	PC3 PrEC2 LNCaP	DU145 PZ-HPV-7 PrEC3 MDAPCa	JT.Hsieh

1. These cell lines in bold were detected positive for murine leukemia virus sequences in their late passage of cultures (see the Results).
2. The human colon carcinoma RKO culture from another source (Gazdar lab, originally from the American Type Culture Collection, Manassas, VA)(Sup. Ref. 2) was negative for XMLV and XMRV, implying XMRV contamination in the RKO culture from Maitra lab (see the Results).

Table S3. Primer sequences

Assays used	Primer Label	Sequence from 5'	Reference gene	Acc. No.	Location (nt)	Suppl. Ref.
MLV Sequencing	GagF1	GCGCCAGTCATCCGATAGACT	MTCR	X94150	1 to 21	3
MLV Sequencing	XS FM1_2 F	ACCTGGGAGGCTATTGCCTATGAA	MTCR	X94150	890 to 913	This report
MLV Sequencing	XS3	CGCCGAAACCGCGCCGCGCGT	MTCR	X94150	551 to 571	3
MLV Sequencing	XS4	TCGTCGCCCCGGACTGCCTTTCTG	MTCR	X94150	1507 to 1530	3
MLV Sequencing	XS FM2_3 F	TGCCTTAATCGAGTCTGTCCTCAC	MTCR	X94150	1396 to 1419	This report
MLV Sequencing	XS FM4_5 F	AGTTAAAGGCCAGATCCACTTCG	MTCR	X94150	2528 to 2561	This report
MLV Sequencing	XS FM4_5 R	TCTTCCACCCGCTTGTTGACTTCT	MTCR	X94150	2962 to 2985	This report
MLV Sequencing	XS FM1_2 R1	GGTCAATGAGAGGTCGCCATTAT	MTCR	X94150	1080 to 1103	This report
MLV Sequencing	VP62 2964F	TGCCCAACCCTTACAACCTCTTGA	XMRV VP62	EF185282.1	2964 to 2987	This report
MLV Sequencing	VP62 4263R	AGGCTTGGGTGAGTGCTATCAGTT	XMRV VP62	EF185282.1	4263 to 4286	This report
MLV Sequencing	Gag F2	GCAGCCCTGGGAGACGTC	XMRV VP62	EF185282.1	362 to 380	4
MLV Sequencing	Gag R2	CGGCGCGGTTTCGGCG	XMRV VP62	EF185282.1	520 to 536	4
MLV Sequencing	XS14	CATGGAAAGTCCAGCGTTCT	MTCR	X94150	5784 to 5803	3
MLV Sequencing	XS15	AGCTGCTCGAATTGTTTGGT	MTCR	X94150	7210 to 7229	3
XMRV qGag	GagQ2F2	AACCGTTTGTCTCTCCTAAACCC	XMRV, VP62	EF185282.1	900 to 922	5
XMRV qGag	GagQ2R2	GCAGGGTAAAGGGCAGATCG	XMRV, VP62	EF185282.1	980 to 999	5
XMRV qGag	Gag Q2P2	5'-FAM ACCGACAGCTCCCGTCTCCCG BHQ-1	XMRV, VP62	EF185282.1	931 to 952	5
MLV qGPP	MLV Q4F4	GCCTGTCCAGGATCTGAGAG	MTCR	X94150	2944 to 2963	This report
MLV qGPP	MLV Q4R4	GAGGTTGTAAGGGTTGGGCA	MTCR	X94150	3000 to 3019	This report
MLV qGPP	MLV Q4P4	5'-FAM AAGTCAACAAGCGGGTGAAGA BHQ-1	MTCR	X94150	2964 to 2985	This report
XMLV qEnv	MLV Q1F1	GGCAGGAGCCTCGGTACAA	MTCR	X94150	5868 to 5886	6
XMLV qEnv	MLV Q1R1	TGTCATTAGTTGGTAACTCTCCAAGT	MTCR	X94150	5917 to 5943	6
XMLV qEnv	MLV Q1P1	5'-FAM TGACAGCCCTCACCAGGTCTTCAATG BHQ-1	MTCR	X94150	5889 to 5914	6
human GAPDH qPCR	hGAPDH gD F1	CCCCACACACATGCACTTACC	human GAPDH	NM_002046	chr12:6645040-6645061	7
human GAPDH qPCR	hGAPDH gD R1	CCTAGTCCCAGGGCTTTGATT	human GAPDH	NM_002046	chr12:6645096-6645115	7
human GAPDH qPCR	hGAPDH gD P1	5'-FAM AAAGAGCTAGGAAGGACAGGCAACTTGGC BHQ-1	human GAPDH	NM_002046	chr12:6645117-6645137	7
TM-PERT	MS2 RT F1	AACATGCTCGAGGGCCTTA	MS2 phage	NC_001417.2	1042 to 1060	8,9
TM-PERT	MS2 RT R1	GCCTTAGCAGTGCCCTGTCT	MS2 phage	NC_001417.2	1163 to 1181	8,9
TM-PERT	MS2 RT P1	5'-FAM CCCGTGGGATGCTCCTACATGTCA BHQ-1	MS2 phage	NC_001417.2	1066 to 1089	8,9
mouse GAPDH PCR	mGAPDH F1	AGTATGATGACATCAAGAAGG	mouse GAPDH*	NM_008084	chr6:125112397-125112414	10
mouse GAPDH PCR	mGAPDH R1	ATGGTATCAAGAGAGTAGGG	mouse GAPDH*	NM_008084	chr6:125112892-125112913	10

*: Multiple copies of mouse GAPDH pseudogenes in mouse genome and mouse GAPDH PCR products (406 or 408 bp) without intron sequences were amplified by these primers (see Figure S2). MLV: murine leukemia virus; XMLV: xenotropic MLV; XMRV: XMLV-related virus; MTCR: murine type C retrovirus; TM-PERT: Taqman fluorogenic 5'-nuclease product-enhanced reverse transcriptase assay.

Table S4. Summary of nucleotide sequence differences between XMRV RKO isolate and XMRV VP62 viral genome and the corresponding sequences in other known XMRV strains

nt position	RKO¹ (1 to 8172 nt)	VP62 (5-8174 nt)	VP35 (1-8185 nt)	VP42 (1-8185 nt)	WPI-1106 (41-8147 nt)	WPI-1178 (41-8147 nt)	22Rv1 (1-8185 nt)
790	A	G	G	A	G	G	A
1104	T	C	C	C	C	C	C
1476	C	T	T	T	T	T	T
1824	G	A	A	G	A	A	G
4264	A	G	G	G	G	G	G
7699	T ins	-	T ins	T ins	-	T ins	T ins
7782	G ins	-	G ins	G ins	-	G ins	G ins
8112	G	C	C	C	C	C	C

1. The full provirus genome sequence of XMRV identified in the viral-positive RKO culture were the same as XMRV VP62 (>99.8% homology) except those nucleotide (nt) positions described in this Table. The RKO genomic DNA contains both XMRV provirus as well as minor variant form(s) of XMRV. The minor mutant forms of XMRV RKO (about 10-25% of XMRV provirus) contains G to A transition hypermutation in numerous sites (estimated 80-100 nt sites) cross XMRV RKO viral genome ,based on DNA sequencing analyses (see Materials and Methods). GeneBank: XMRV VP62 (EF185282.1), XMRV VP35 (DQ24241301), XMRV VP42 (DQ241302), WPI-1106 (GQ497344.1), WPI-1178 (GQ497343.1), and 22Rv1 (emb|FN692043.1), XMRV RKO (JF274252).

Table S5. Identifications of xenotropic murine leukemia viruses (XMLV) sequences in the cells infected with the XMLV-positive supernatants¹

Cell Cultures	Input DNA (ng)	Ct of human qGAPDH	Ct of MLV qEnv	Ct of MLV qGag	Ct of MLV qGPP
LAPC-4	100	28.5	28.7	34.1	28.4
NCI-N417	100	27.8	21.1	Neg.	21.6
1065met	100	27.0	27.0	31.4	31.3
H1299_ Unt d7	100	27.1	Neg.	Neg.	Neg.
H1299_ Unt d14	100	27.2	Neg.	Neg.	Neg.
H1299_LAPC4 d7	100	27.4	28.9	Neg.	28.9
H1299_LAPC4 d14	100	27.0	27.1	Neg.	27.3
H1299_N417 d7	100	27.1	27.2	Neg.	27.5
H1299_N417 d14	100	26.7	27.8	Neg.	27.8
H1299_1065met d7	100	27.1	26.8	37.0	32.4
H1299_1065met d14	100	26.8	27.3	36.9	32.6
H69_ Unt d14	100	28.1	Neg.	Neg.	Neg.
H69_LAPC4 d14	100	28.0	26.4	Neg.	26.2
H69_N417 d14	100	27.7	25.1	Neg.	25.1
H69_1065met d14	100	27.9	24.0	36.6	29.0
H1092_ Unt d14	100	28.0	Neg.	Neg.	Neg.
H1092_LAPC4 d14	100	27.5	29.2	Neg.	29.2
H1092_N417 d14	100	27.6	27.4	Neg.	27.7
H1092_1065met d14	100	27.5	25.1	37.3	30.9
H460_ Unt d18	100	28.6	Neg.	Neg.	Neg.
H460_LAPC4 d18	100	28.2	Neg.	Neg.	Neg.
H460_N417 d18	100	27.9	38.3	Neg.	38.5
H460_1065met d7	100	28.0	32.6	38.4	37.3
H460_1065met d18	100	27.7	31.5	38.2	36.1
HBEC3 Unt d18	100	27.4	Neg.	25.8	Neg.
HBEC3_LAPC4 d18	100	26.9	Neg.	26.1	Neg.
HBEC3_N417 d18	100	27.5	Neg.	25.8	Neg.
HBEC3_1065met d7	100	28.3	27.8	26.3	33.2
HBEC3_1065met d18	100	27.4	26.2	25.1	32.5

1. Supernatant fluids from three xenograft XMLV-positive cultures (LAPC-4, NCI-N417 and 1065met)(Sup. Table S1) were used to infect four XMLV free lung cancer cultures (NSCLC lines NCI-H1299 and NCI-H460; SCLC lines NCI-H69 and NCI-H1092) and an immortalized human bronchial epithelial cell culture HBEC3KTR53 (HBEC3) (Sup. Ref. 11). The DNA after infections was isolated and examined by MLV qPCR with three viral probes and human GAPDH internal controls (see Materials/Methods and Sup. Table S3). The uninfected HBEC3 culture was positive for the *gag* region of MLV, presumably as a result of the retrovirus vectors for TERT and CDK4 used to immortalize the cells (Sup. Ref. 11). Unt: uninfected. d: day post-infection.

A. qGag

	890	900	910	920	930	940	950	960
22Rv1	CCATATATCGTCACTGGGAGGCACCTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTCTCTCTAAACC							
VP62	CCATATATCGTCACTGGGAGGCACCTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTCTCTCTAAACC							
DG-75	CCATACATTGTCACCTGGGAGGCACCTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTCTCTCTAAACC							
SP(B)1-2	CCATATACCGTCACTGAGGGCCTGACCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTCTCTCTAAATC							
MTCR	CCATACATTGTCACCTGGGAGGCATTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTCTCTCTAAACT							
N417	CCATACATTGTCACCTGGGAGGCATTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTCTCTCTAAACT							
AKV	CCATATATGTCACCTGGGAGGCATTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTCTCTCTAAACT							
MoloneyMLV	CCCTACATCGTACCTGGGAGGCATTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTACACCTAAGCCTCGCC							
FriendMLV	CCCTACATCGTACCTGGGAGGCATTTGCCTATGACCCCCCTCCGTTGGGTCAAACCGTTTGTACACCTAAGCCTCGCC							
Prim.cons.	CCATACAT2GTCACTGGGAGGCATTTGCCTATGACCCCCCTCCGTTGGGTCAAAC2T1TGTCTCTCTAAACCTCC2C2							

	970	980	990	1000	1010	1020	1030	1040
22Rv1	CCCTCCTTTACCGACAGCTCCCGTCTCCCGCCCGGTCTTCTGCGCAACCTCCGTCGGATCGCCCTTACCTGGCC							
VP62	CCCTCCTTTACCGACAGCTCCCGTCTCCCGCCCGGTCTTCTGCGCAACCTCCGTCGGATCGCCCTTACCTGGCC							
DG-75	CCCTCCTTTACCGACAGCTCCCGTCTCCCGCCCGGTCTTCTGCGCAACCTCCGTCGGATCGCCCTTACCTGGCC							
SP(B)1-2	CCCTCCTTTACCGACAGCTCCCGTCTCCCGCCCGGTCTTCTGCGCAACCTCCGTCGGATCGCCCTTACCTGGCC							
MTCR	CTCCCTCTCTCAACCGCTCCCATCTCCCATCCCGGTCTTCTGACCAACCTCCGCCCGATCTGCCCTTACCTGGCT							
N417	CTCCCTCTCTCAACCGCTCCCATCTCCCATCCCGGTCTTCTGACCAACCTCCGCCCGATCTGCCCTTACCTGGCT							
AKV	CTCCCTCTCTCAACCGCTCCCATCTCCCATCCCGGTCTTCTGACCAACCTCCGCCCGATCTGCCCTTACCTGGCT							
MoloneyMLV	TCCTTCTCCTCAATCCCGCTCTCCCGCTTGAACCTCCGTCGTCGACCCGCCCTCGATCTCCCTTATCCAGGCC							
FriendMLV	TCCTTCTCCTCAATCCCGCTCTCCCGCTTGAACCTCCGTCGTCGACCCGCCCTCGATCTCCCTTATCCAGGCC							
Prim.cons.	C2CTC2TTC2CAAC2GCTCC2TCTCCACCCGGTCTTCT2CCAACCTCCGCCCGATCTGCCCTTACCTGG2C2							

B. qGPP

	2890	2900	2910	2920	2930	2940	2950	2960
22Rv1	ACTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
VP62	ACTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
DG-75	ACTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
MTCR	ATTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
N417	ATTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
AKV	ACTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
MoloneyMLV	ACTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
FriendMLV	ACTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							
Prim.cons.	ACTGGTACCCTGCCAGTCCCCTGGAAACAGCCCCCTGCTACCCGTTAAGAAACCAGGACTAATGATTATAGGCCTGTCC							

	2970	2980	2990	3000	3010	3020	3030	3040
22Rv1	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
VP62	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
DG-75	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
MTCR	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
N417	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
AKV	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
MoloneyMLV	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
FriendMLV	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							
Prim.cons.	AGGATCTGAGAGAAGTCAACAAGCGGGTGAAGACATCCACCCACCGTGCCCAACCCCTTACAACCTCTTGGCGGGCTC							

C. qEnv

	5850	5860	5870	5880	5890	5900	5910	5920
22Rv1	AGATTAACCCGTTGGGCCCCCTGATAATTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCAGTACAACGTGAC							
VP62	AGATTAACCCGTTGGGCCCCCTGATAATTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCAGTACAACGTGAC							
DG-75	AGATTAACCCGTTGGGCCCCCTAATAGTTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCGGTACAACGTGAC							
MTCR	AGATTAACCCGTTGGGCCCCCTAATAGTTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCGGTACAACGTGAC							
N417	AGATTAACCCGTTGGGCCCCCTAATAGTTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCGGTACAACGTGAC							
AKV	AGGTTAACCCTGGGGCCCTAATAGTTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCGGTACAACGTGAC							
MoloneyMLV	AGGTTAACCCTGGGGCCCTAATAGTTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCGGTACAACGTGAC							
FriendMLV	AGGTTAACCCTGGGGCCCTAATAGTTATGGGGATCTTGGTG-----AGGGCAGGAGCCTCGGTACAACGTGAC							
Prim.cons.	AGATTAACCCGTTGGGGCCCTAATAGTTATGGGGATCTTGGTGCTCTCA2AAGGGCAGGAGCCTC2GTACAACGTGAC							

	5930	5940	5950	5960	5970	5980	5990	6000
22Rv1	AGCCCTCACAGGCTCTTAATGTCACCTGGAAAATTACCAA-----CCTAATGACAGGACAAACAGCTAATGCTACCTC							
VP62	AGCCCTCACAGGCTCTTAATGTCACCTGGAAAATTACCAA-----CCTAATGACAGGACAAACAGCTAATGCTACCTC							
DG-75	AGCCCTCACAGGCTCTCAATGTTACTTGGAGAGTTACCAA-----CCTAATGACAGGACAAACAGCTAATGCTACCTC							
MTCR	AGCCCTCACAGGCTCTCAATGTTACTTGGAGAGTTACCAA-----CCTAATGACAGGACAAACAGCTAATGCTACCTC							
N417	AGCCCTCACAGGCTCTCAATGTTACTTGGAGAGTTACCAA-----CCTAATGACAGGACAAACAGCTAATGCTACCTC							
AKV	AGCCCTCACAGGCTCTTAATGTCACCTGGAAAATTACCAA-----CCTAATGACAGGACAAACAGCTAATGCTACCTC							
MoloneyMLV	AGTCTCATCAGTCTAATAATACCTGGGAGGTAACTAATGGAGATCGGGAGACGATATGGGCAACTCTGGGCAACCA							
FriendMLV	AGTCTCATCAGTCTAATAATACCTGGGAGGTAACTAATGGAGATCGGGAGACGATATGGGCAACTCTGGGCAACCA							
Prim.cons.	AGCCCTCACAGGCTCT2AATGTCACCTGGAAAATTACCAATGGAGACTAATGACAGGACAAAC2CTAACGC2ACCTC							

Figure S1. Illustration of locations of the primers/probe for MLV qGag, qGPP and qEnv PCR. The representative XMRV viruses (22Rv1 and VP62), xenotropic MLV (SP(B) 1-2, DG-75, MTCR and N417), ecotropic MLV (AKV, MoloneyMLV and FriendMLV) are compared to the primers (bold, underlined, green highlight)/probes (bold, underline, blue highlight) sequences (see also Table S3) in Figure S1A., B. and C., for MLV qGag, qGPP and qEnv PCR, respectively. Nt no. refers to an approximate nt position in each viral genome. GeneBank Accession no.: XMRV 22Rv1 (emb|FN692043.1), XMRV VP62 (EF185282.1), MLV DG-75 (AF221065.1), MLV SP(B) 1-2 (AY349140.1), MTCR (X94150.1), MLV N417 (HQ246218), MLV AKV (J01998.1), Moloney MLV (AF033811.1) and Friend MLV (NC_001362.1).




Figure S2. Determination of mouse DNA detection sensitivity of the PCR assay specific for mouse GAPDH. The PCR reaction contained mouse spleen DNA (ranging from 1 ng to 0.1 fg) plus salmon sperm carrier DNA (100 ng), or salmon sperm carrier DNA alone. The mouse DNA were detectable at amount of as low as 0.1 pg to 0.01 pg. The amplified 406 bp (or 408) bp PCR product were sequenced and confirmed to correspond to mouse GAPDH pseudogene which is present with multiple copies in mouse genomes (see Materials/Methods and Table S3). Interestingly, the amplified PCR product of mouse genomic DNA was about 406 bp to 408 bp, which was differently from 506 bp as predicted from mouse GAPDH gene on chromosome 6 (GeneBank Accession no. NM_008084) (Figure 2). The reason for yielding a shorter PCR product appears due to the presence of numerous copies (>250) of mouse GAPDH pseudogene in many different chromosomes in mouse genome, for examples, the genes of Gene Accession no AL732526.8 (chromosome 2), NG_005467.5 (chromosome 5), NG_007762.3 (chromosome 8), NG_005468.5 (chromosome 7), NG_007811.1(chromosome 15) and NG_007228.1 (chromosome 4). The amplified PCR products from mouse spleen DNA were confirmed to match mouse GAPDH pseudogene by DNA sequencing. Under our PCR conditions, the mouse GAPDH PCR is highly sensitive and able to detect 0.1 pg to 0.01 pg of mouse DNA.


```

LOCUS      1065met_XS1/GagR2      555 bp
ORIGIN
1   TCCGATAGAC TGAGTCGCC  GGGTACCCGT GTATCCAATA AAGCCTTTTG CTGTTGCATC
61  CGAATCGTGG TCTCGCTGAT CCTTGGGAGG GTCTCCTCAG AGTGATTGAC TGCCAGCCT
121 GGGGTCTTTT CATTGGGGG  CTCGTCCGGG ATTTGGAGAC CCCCGCCAG  GGACCACCGA
181 CCCACCGTCG GGAGGTAAGC TGGCCAGCGA TCGTTTTGTC TCCGTCTCTG TCTTTGTGCG
241 TGTGTGTGTG TGTGCCGGCA TCTACTTTT  GCGCCTGCGT CTGATTCTGT ACTAGTTAGC
301 TAACTAGATC TGTATCTGGC GGCTCCGTGG AAGAAGTACG GAGTTCGTAT TCCCGACCGC
361 AGCCCTGGGA GACGTCTCAG AGGCATCGGG GGCCCGCTGG GTGGCCCAAT CAGTAAGTCC
421 GAGTCCTGAC CGATTCCGAC TATTTGGGGC CCCTCCTTTG TCGGAGGGGT ACGTGGTTCT
481 TTTAGGAGAC GAGAGGTCCA AGCCCTCGCC GCCTCCATCT GAATTTTTCG TTTCCGTTT
541 TCGCCGAAAC CGCGC

```

//

```

LOCUS      1065met_XS3/XS4      831 bp
ORIGIN
1   TTGGACCGCT TCTAAAAACA TGGGACAGAC CGTAACCACC CCTCTGAGTC TGACCCTAGA
61  AACTGGAAA  GATGTCCAGC GCATCGGTC  CAATCAGTCC GTAGATGTCA AGAAGAGACG
121 CTGGGTCAAC TTCTGTCTCT CCGAGTGGCC AACTTTCGGT GTAGGGTGGC CACAAGATGG
181 TACTTTTAAT TTGGACATTA TTCTACAGGT TAAATCTAAG GTGTCTCTCT CTGGTCCCCA
241 CGGACACCCG GATCAGGTCC CATATATTGT CACCTGGGAG GCTATTGCCT ATGAACCCCC
301 TCCGTGGGTC AAACCTTTTG TCTCTCCCAA ACTCTCCCC  TCTCAACCG  CTCCATCCT
361 CCTATCCGGT CTTTCGACCC AACCTCCGCC CCGATCTGCC CTTTACCCTG CTCTTACCCC
421 CTCTATAAAA CCCAGACCTT CTAACCTCA  GGTCTCTCC  GATAATGGCG GACCTCTCAT
481 TGACCTTCTC TCAGAAGACC CTCCGCCGTA CCGAGGACAG GGACTGTCTC CTCTGGACGG
541 AGATGGCGAC AGAGAAGAGG CCACCTCCAC TTCTGAGATT CCTGCCCCCT CTCCATAGT
601 GTCTCGCCTG CGGGGCAAAA GAGACCCCC  CGCGGCAGAT TCCACCACCT CTCTGGCTTT
661 CCCACTCCGT TTGGGGGGTA ATGGTCAGTT GCAGTACTGG CCGTTTTCCT CCTCTGATCT
721 ATATAACTGG AAAAAATAATA ATCCTTCCTT CTCTGAGGAT CCAGGTA AAC TGACTGCATT
781 GATTGAATCC GTCCTCACCA CCCACCAGCC CACCTGGGAT GATTGCCAGC A

```

//

```

LOCUS      1065met_XS14/XS15    1338 bp
ORIGIN
1   TAATAGTTAT GGGGATCTTG GTGAGGGCAG GAGCCTCGGT ACAACGTGAC AGCCCTCACC
61  AGATCTTCAA TGTACTTGG  AGAGTTACCA ACCTAATGAC AGGACAAAACA GCTAACGCCA
121 CCTCCCTCCT GGGGACGATG ACAGACACCT TCCCTAAACT ATATTTTGAC CTGTGTGATT
181 TAGTAGGAGA CTA CTACTGGGAT GACCCAGAAC CCGATATTGG GGATGGTTGC CGCACTCCCG
241 GGGGAAGAAG AAGGACAAGA CTGTATGACT TCTATGTTTG CCCC GGTCAT ACTGTACCAA
301 TAGGGTGTGG AGGGCCGGGA GAGGGCTACT GTGGCAAATG GGGATGTGAG ACCACTGGAC
361 AGGCATACTG GAAGCCATCA TCATCATGGG ACCTAATTTT CCTTAAGCGA GGAACACTC
421 CTAAGGATCA GGGCCCTGT TATGATTCCT CGGTCTCCAG TGGCGTCCAG GGTGCCACAC
481 CGGGGGTTCG ATGCAACCCC CTGGTCTTAG AATTCACTGA CGCGGGTAGA AAGGCCAGCT
541 GGATGCCCC  CAAAGTTTGG GGACTAAGAC TCTATCGATC CACAGGGGCC GACCCGGTGA
601 CCCGGTTCTC TTTGACCCGC CAGGTCCTCA ATGTAGGACC CCGCGTCCCC ATTGGGCCTA
661 ATCCCGTGAT CACTGACCAG CTACCCCAT  CCCAACCCGT GCAGATCATG CTCCCAGGC
721 CTCTCATCC  TCCTCCTTCA GGCACGGTCT CTATGGTACC TGGGGTCCC  CCGCTTCTC
781 AACAACTGG  GACGGGAGAC AGGCTGCTAA ATCTGGTAGA AGGAGCTTAC CAAGCACTCA
841 ACCTCACCAG TCCTGACAAA ACCCAAGAGT GCTGGTTGTG TCTGGTATCG GGACCCCTC
901 ACTACGAAGG GGTGCGGTC CTAGGTACCT ACTCCAACCA TACTCTGCC  CCAGCTAACT
961 GTCCTGGTGG CTCCCAACAC AAGCTGACCC TGTCCGAAGT AACCGGACAG GGACTCTGCG
1021 TAGGAGCAGT TCCAAAACC  CATCAGGCC  TGTGTAATAC CACCCAGAAG ACGAGCGACG
1081 GGTCTACTA  TCTGGCTGCT CCCGCCGGA  CCATCTGGGC TTGCAACACC GGGCTCACTC
1141 CTGCCTATC  TACTACTGTA CTCAACCTCA CCACCGATTA CTGTGTCTG  GTTGAGCTCT
1201 GGCCAAAGGT GACCTACCAC TCCCTGGTT  ATGTTTATGG CCAGTTTGG  AGAAAAACCA
1261 AATATAAAG  AGAGCCGGTG TCATTAATC  TGGCCTGCT  GTTAGGAGGA CTTACTATGG
1321 GCGGCATAGC TGCAGGAG

```

//

Figure S3. MLV-related sequences detected in 1065met lung cancer xenograft cell line. The sequencing data were obtained by sequencing of XS1/GagR2 (5' end, 555 nts), XS3/XS4 (gag, 831 nts) and XS14/XS15 (env, 1338 nts) PCR products of 1065met DNA (see Table S3 for details). The sequence at the 5' end and gag gene has 99% homology to AKV murine leukemia virus (GeneBank Accession no. J01998.1), and the sequence at env gene region has 99% homology to Murine xenotropic virus NZB (GeneBank Accession no EU33447.1).

```

      10      20      30      40      50      60      70      80
H82_XS1_GagR2 -----TCTCGCTGATCCTTGGGAGGGTCTCCTCAGAGTGATTGACTGCCAGCCTGG
H146_XS1_GagR2 -----TCTCGCTGATCCTTGGGAGGGTCTCCTCAGAGTGATTGACTGCCAGCCTGG
LX47_XS1_GagR2 -CCTTTTGTCTGTGCATCCGAATCGTGGTCTCGCTGATCCTTGGGAGGGTCTCCTCAGAGTGATTGACTGCCAGCCTGG
LX48_XS1_GagR2 CCTTTTGTCTGTGTGCATCCGAACCTGGCCTCGCTGTTCCTTGGGAGGGTCTCCTCAGAGTGATTGACTGCCAGCCTGG
          *****
Prim.cons.      CC2TTT2222TTGCATCCGAA2CGTGGTCTCGCTGATCCTTGGGAGGGTCTCCTCAGAGTGATTGACTGCCAGC2TGG

      90      100     110     120     130     140     150     160
H82_XS1_GagR2 GGGTCTTTCATTGGGGGCTCGTCCGGGATTGGAGACCCCGCCAGGGACCACCGACCCACCGTCGGGAGGTAAGCTG
H146_XS1_GagR2 GGGTCTTTCATTGGGGGCTCGTCCGGGATTGGAGACCCCGCCAGGGACCACCGACCCACCGTCGGGAGGTAAGCTG
LX47_XS1_GagR2 GGGTCTTTCATTGGGGGCTCGTCCGGGATTGGAGACCCCGCCAGGGACCACCGACCCACCGTCGGGAGGTAAGCTG
LX48_XS1_GagR2 GGGTCTTTCATTGGGGGCTCGTCCGGGATTGGAGACCCCGCCAGGGACCACCGACCCACCGTCGGGAGGTAAGCTG
          *****
Prim.cons.      GGGTCTTTCATTGGGGGCTCGTCCGGGATTGGAGACCCCGCCAGGGACCACCGACCCACCGTCGGGAGGTAAGCTG

      170     180     190     200     210     220     230     240
H82_XS1_GagR2 GCCAGCGATCGTTTTGTCTCCGTCTCTGTCTTTGTGCGTGTGTGTGTGTGCCGGCACCTACTTTTTGCGCCTCGCTCT
H146_XS1_GagR2 GCCAGCGATCGTTTTGTCTCCGTCTCTGTCTTTGTGCGTGTGTGTGTGTGCCGGCACCTACTTTTTGCGCCTCGCTCT
LX47_XS1_GagR2 GCCAGCGATCGTTTTGTCTCCGTCTCTGTCTTTGTGCGTGTGTGTGTGTGCCGGCACCTACTTTTTGCGCCTCGCTCT
LX48_XS1_GagR2 GCCAGCGATCGTTTTGTCTCCGTCTCTGTCTTTGTGCGTGTGTGTGTGTGCCGGCACCTACTTTTTGCGCCTCGCTCT
          *****
Prim.cons.      GCCAGCGATCGTTTTGTCTCCGTCTCTGTCTTTGTGCGTGTGTGTGTGTGCCGGCA2CTACTTTTTGCGCCTCGCTCT

      250     260     270     280     290     300     310     320
H82_XS1_GagR2 GATTCTGTACTAGTTAGCTAACTAGATCTGTATCTGGCGGCTCCGTGGAAGAAGTACGAGTTCGTATTCCCGACCCGAG
H146_XS1_GagR2 GATTCTGTACTAGTTAGCTAACTAGATCTGTATCTGGCGGCTCCGTGGAAGAAGTACGAGTTCGTATTCCCGACCCGAG
LX47_XS1_GagR2 GATTCTGTACTAGTTAGCTAACTAGATCTGTATCTGGCGGTTCCGTGGAAGAAGTACGAGTTCGTATTCCCGACCCGAG
LX48_XS1_GagR2 GATTCTGTACTAGTTAGCTAACTAGATCTGTATCTGGCGGTTCCGTGGAAGAAGTACGAGTTCGTATTCCCGACCCGAG
          *****
Prim.cons.      GATTCTGTACTAGTTAGCTAACTAGATCTGTATCTGGCGG2TCCGTGGAAGAAGTACGAGTTCGTATTCCCGACCCGAG

      330     340     350     360     370     380     390     400
H82_XS1_GagR2 CCCTGGGAGACGTCTCAGAGGCATCGGGGGCCCGCTGGGTGGCCCAATCAGTAAAGTCCGAGTCCTGACCGATTCCGGACTA
H146_XS1_GagR2 CCCTGGGAGACGTCTCAGAGGCATCGGGGGCCCGCTGGGTGGCCCAATCAGTAAAGTCCGAGTCCTGACCGATTCCGGACTA
LX47_XS1_GagR2 CCCTGGGAGACGTCTCAGAGGCATCGGGGGCCCGCTGGGTGGCCCAATCAGTAAAGTCCGAGTCCTGACCGATTCCGGACTA
LX48_XS1_GagR2 CCCTGGGAGACGTCTCAGAGGCATCGGGGGCCCGCTGGGTGGCCCAATCAGTAAAGTCCGAGTCCTGACCGATTCCGGACTA
          *****
Prim.cons.      CCCTGGGAGACGTCTCAGAGGCATCGGGGGCCCGCTGGGTGGCCCAATCAGTAAAGTCCGAGTCCTGACCGATTCCGGACTA

      410     420     430     440     450     460     470     480
H82_XS1_GagR2 TTTGGGGCCCTCCTTTGTGCGGAGGGGTACGTGGTTCCTTTAGGAGACGAGAGGTCCAAGCCCTCGCCGCTCCATCTGA
H146_XS1_GagR2 TTTGGGGCCCTCCTTTGTGCGGAGGGGTACGTGGTTCCTTTAGGAGACGAGAGGTCCAAGCCCTCGCCGCTCCATCTGA
LX47_XS1_GagR2 TTTGGGGCCCTCCTTTGTGCGGAGGGGTACGTGGTTCCTTTAGGAGACGAGAGGTCCAAGCCCTCGCCGCTCCATCTGA
LX48_XS1_GagR2 TTTGGAGCCCTCCTTTGTGCGGAGGGGTACGTGGTTCCTTTAGGAGACGAGAGGTCCAAGCCCTCGCCGCTCCATCTGA
          *****
Prim.cons.      TTTGGGGCCCTCCTTTGTGCGGAGGGGTACGTGGTTCCTTTAGGAGACGAGAGGTCCAAGCCCTCGCCGCTCCATCTGA

      490     500
H82_XS1_GagR2 ATTTTGTCTTTCGGTTTTTCGC
H146_XS1_GagR2 ATTTTGTCTTTCGGTTTTTCGC
LX47_XS1_GagR2 ATTTTGTCTTTCGGTTTTTC--
LX48_XS1_GagR2 ATTTTGTCTTTCGGTTTTTC--
          *****
Prim.cons.      ATTTTGTCTTTCGGTTTTTCGC

```

Figure S4. Alignment analysis of the MLV-related sequences detected in LX47 and LX48 lung cancer xenograft lines and the contaminated NCI-H82 and NCI-H146 non-xenograft lines. The sequencing data were obtained by sequencing of XS1/GagR2 PCR products of each sample (see Table S1 S2 and S3 for details). The additional sequencing of XS3/XS4 PCR products showed the same sequences for viral positive NCI-H82 and NCI-H146. The LX47, NCI-H820 and NCI-H146 contain near identical MLV-related sequences which have 100% homology to *Mus musculus* endogenous ecotropic murine leukemia virus 1 (GeneBank Accession no. DQ366147.1) and 99% homology to AKV murine leukemia virus (GeneBank Accession no. J01998.1). The sequence at env gene region (XS14/XS15 PCR, not shown) were the same between LX47 and the positive NCI-H820 and has 99% homology to Murine xenotropic virus NZB (GeneBank Accession no EU33447.1). LX48 sequencing data is different from LX47 has 99% homology to Murine leukemia virus MCF1233 (GeneBank Accession no. MLU13766).

```

LOCUS      CAK1_XS3_XS4      903 bp
ORIGIN
1  GTCATTTGTC  GGTTCTGTTAT  TGTTTTGGAC  CGTTTCTAAA  AATATGGGAC  AGACCGTAAC
61  CACTCCTTTG  AGTCTGACCC  TAGAACAAC  GGGAGACGTC  CAGCGCATG  CGTCCAACCA
121  GTCCTGGGAC  GTCAAGAAGA  GACGTTGGGT  CACCTTCTGC  TCTGCCGAGT  GGCCAACCTT
181  CGATGTGGGG  TGGCCGCAAG  ATGGTACTTT  TAATTGGAC  ATTATTTTAC  AGGTTAAATC
241  TAAGGTGTTC  TCTCCCGGTC  CCCACGGACA  CCCGGATCAG  GTCCCATACA  TTGTCACCTG
301  GGAGGCACTT  GCCTATGACC  CCCCTCCGTG  GGTCAAACCG  TTTGTCTCTC  CAAAACCCCC
361  TCCTTTACCG  ACAGCTCCCG  TCCTCCCGCC  CGGTCTTCT  GCGCAACCTC  CGTCCCGATC
421  TGCCCTTTAC  CCGTCCCTTA  CCCCTCTAT  AAAGACCAA  CCTCCTAAGC  CCCAGTTTCT
481  CCCTGATAAC  GGCGGACCGC  TCATTGACCT  TCTCACAGAG  GACCCCCCGC  CGTACGGAGC
541  ACAACCTTCC  TCCTCTGCCA  GAGGGAACGA  TGAAGAAGAG  GCGGCCGCCA  CCTCCGAGGT
601  TTCCTCCCTC  TCTCCCATGG  TGTCTCGACT  GCGGGGAAGG  AGGGACCTCC  CCGCAGCGGA
661  CTCACCTTCC  TCCCAGGCAT  TCCCCTCCG  CATGGGGGGA  GATGGCCAGC  TTCAGTATTG
721  GCCGTTTTCC  TCCTCGGACT  TATACAATTG  GAAAAATAAT  AACCTTCTCT  TTCTGAAGA
781  CCCAGGTAAA  TTGACGGCCT  TGATTGAGTC  CGTCTCATC  ACCCACCAGC  CCACCTGGGA
841  CGACTGTGAG  CAGTTGTTGG  GGACCTGCT  GACCGGAGAA  GAAAAGCAGC  GGGTGCTCCT
901  AGA

```

//

```

LOCUS      CAK1_XS14_XS15    1352 bp
ORIGIN
1  GTGGGGCCCC  CTAATAGTTA  TGGGGATCTT  GGTGAGGGCA  GGAGCTCGG  TACAACGTGA
61  CAGCCCTCAC  CAGATCTTCA  ATGTTACTTG  GAGAGTTACC  AACCTAATGA  CAGGACAAC
121  AGCTAACGCC  ACCTCCCTCC  TGGGGACGAT  GACWGACACC  TTCCTAAAC  TATATTTTGA
181  CCTGTGTGAT  TAGTAGGAG  ACTACTGGGA  TGACCCAGAA  CCCGATATG  GGGATGGTTG
241  CCGCACTCCC  GGGGGAAGAA  GAAGGACAAG  ACTGTATGAC  TTCTATGTTT  GCCCCGGTCA
301  TACTGTACCA  ATAGGGTGTG  GAGGGCCGGG  AGAGGGCTAC  TGTGGCAAAT  GGGGATGTGA
361  RACCACTGGA  CAGGCATACT  GGAAGCCATC  ATCATCATGG  GACCTAATTT  CCCTTAAGCG
421  AGGAAACACT  CCTAAGGATC  AGGGCCCTGT  TTATGATTCC  TCGGTCTCCA  GTGGCGTCCA
481  GGTGCCCCA  CCGGGGGGTC  GATGCAACCC  CCTGGTCTTA  GAATTCCTG  ACGCGGGTAR
541  AAAGGCCAGC  TGGGATGCC  CCAAAGTTTG  GGGACTRAGA  CTCTATCGAT  CCACAGGGGC
601  CGACCCGGTG  ACCCGTTTCT  CTTTGACCCG  CCAGTCTCT  AATGTAGGAC  CCCCGTCCC
661  CATGTGGGCT  AATCCCCTGA  TCACTGACCA  GCTACCCCA  TCCCAACCCG  TGCAGATCAT
721  GCTCCCCAGG  CCTCCTCATC  CTCCTCTTTC  AGRCACGGTC  TCTATGGTAC  CTGGGGCTCC
781  CCGCCTTCT  CAACAACCTG  GGACGGGAGA  CAGGCTGCTA  AATCTGGTAG  AAGGAGCCTA
841  CCAAGCACTC  AACCTCACCA  GTCCTGACAA  AACCCTAAG  TGCTGGTTGT  GTCTGGTATC
901  GGGACCCCC  TACTACGAAG  GGGTTGCCGT  CCTAGGTACC  TACTCCAACC  ATACCTCTGC
961  CCCAGCTAAC  TGCTCCGTGG  CCTCCCAACA  CAAGCTGACC  CTGTCCGAAG  TGACCGGACA
1021  GGGACTCTGC  GTAGGAGCAG  TTCCCAAAAC  CCATCAGGCC  CTGTGTAATA  CCACCCAGAA
1081  GACGAGCGAC  GGGTCTACT  ATCTGGCTGC  TCCCCTGGG  ACCATCTGGG  CTTGCAACAC
1141  CGGGCTCACT  CCCTGCCTAT  CFACTACTGT  ACTCAACCTC  ACCACCGATT  ACTGTGTCTC
1201  GGTGAGCTC  TGGCCAAAG  TGACCTACCA  CTCCCCTGGT  TATGTTTATG  GCCAGTTTGA
1261  GAAAAAACC  AAATATAAAA  GGGAGCCGGT  GTCATTAACT  CTGGCCCTGC  TGTGGGAGG
1321  ACTTACTATG  GGCGGCATAG  CTGCAGGAGT  AG

```

//

Figure S5. MLV-related sequences detected in CAK1 pancreatic carcinoma xenograft cell line. The sequencing data were obtained by sequencing of XS1/GagR2 (5' end), XS3/XS4 (gag, 903 nts) and XS14/XS15 (env, 1352 nts) PCR products of CAK1 DNA (see Sup. Table S3 for details). The sequence at the 5' end demonstrated wt and possible 1 nt del variant form at about 1:1 ratio. The gag gene and env gene sequencing data both have over 99% homology to DG-75 Murine leukemia virus (GeneBank Accession no AF221065.1).

```

          10      20      30      40      50      60      70      80      90      100
WPI_1106  -----GTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
WPI_1178  -----GTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
VP35      GCGCCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCTGTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
VP62      ----AGTCATCCGATAGACTGAGTCGCCCGGGTACCCTGTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
22Rv1     GCGCCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCTGTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
VP42      GCGCCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCTGTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
RKO       -----GAGTCGCCCGGGTACCCTGTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
MTCR      GCGCCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCTGTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG
*****
Prim.cons. GCGCCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCTGTTCCAATAAAGCCTTTTGCTGTTTGCATCCGAAGCGTGGCCTCGCTGTTCTTGGGAG

          110     120     130     140     150     160     170     180     190     200
WPI_1106  GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
WPI_1178  GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
VP35      GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
VP62      GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
22Rv1     GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
VP42      GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
RKO       GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
MTCR      GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC
*****
Prim.cons. GGTCTCTCAGAGTGATTGACTACCCAGCTCGGGGCTCTTCATTGGGGGCTCGTCCGGGATTCGGAGACCCCGCCAGGGACACCGACCCACCGTC

          210     220     230     240     250     260     270     280     290     300
WPI_1106  GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
WPI_1178  GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
VP35      GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
VP62      GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
22Rv1     GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
VP42      GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
RKO       GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
MTCR      GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA
*****
Prim.cons. GGGAGGTAAGCCGCGCGCGATCGTTTGTCTTTGCTCTGTCTTTGTGCGTGTGTGTGTGCGGCATCTAATCCTCGGCCTCGCTGTAATCTGTA

          310     320     330     340     350     360     370     380     390     400
WPI_1106  CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
WPI_1178  CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
VP35      CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
VP62      CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
22Rv1     CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
VP42      CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
RKO       CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
MTCR      CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG
*****
Prim.cons. CTAGTTAGCTAACTAGATCTGTATCTGGCGTTCCCGGAAGAAGTACGACGAGTTCGTATTCCCGGCCGAGCCCTGGGAGACGTCACAGCGGCCTCGGGG

          410     420     430     440     450     460     470     480     490     500
WPI_1106  GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
WPI_1178  GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
VP35      GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
VP62      GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
22Rv1     GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
VP42      GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
RKO       GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
MTCR      GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG
*****
Prim.cons. GCCCGTTTGTGGGCCATCTGTATCAGTTAA-CCTACCAGTTCGGACTTTTGGAG-----TGGCTTTGTGGGGACG

          510     520     530     540     550
WPI_1106  AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA
WPI_1178  AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA
VP35      AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA
VP62      AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA
22Rv1     AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA
VP42      AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA
RKO       AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA
MTCR      AGAGTCCAGCCCTCGCCCTCCATCTGAATTTTGGCTTTTCGGTTTTT
*****
Prim.cons. AGAGACAGAGACACTTCCCGCCCCGTCTGAATTTTGGCTTTTCGGTTTTA

```

Figure S6. Comparison of sequences at 5' leader region of gag gene between XMRV RKO and the known XMRV strains and xenotropic MLV. XMRV RKO represented an isolate from the RKO cells (Maitra Lab) contaminated with XMRV viruses (see Sup.Table S2). The XMRV RKO sequence, which were obtained from PCR product of RKO genomic DNA using GagF1 and GagR2 primers (Table S3), contain XMRV 24-nt deletion feature as compared with a MTCR XMLV strain and >99.6% homology in 5' leader region of gag gene to all known XMRV strains (WPI-1106, WPI-1178, VP35, VP62 and 22Rv1).

```

          970      980      990      1000     1010     1020
MLV N417      TCCAACCGCTCCCATCCTCCCATCCGGTCCTTCGACCCAACCTCCGCCCCGATCTGCCCT
MTCR          TCCAACCGCTCCCATCCTCCCATCCGGTCCTTCGACCCAACCTCCGCCCCGATCTGCCCT
LAPC-4 (2010) -----CCGCCCCGATCTGCCCT
LAPC-4 (1998) TCCAACCGCTCCCATCCTCCCATCCGGTCCTTCGACCCAACCTCCGCCCCGATCTGCCCT
                    *****
Prim. cons.   TCCAACCGCTCCCATCCTCCCATCCGGTCCTTCGACCCAACCTCCGCCCCGATCTGCCCT

          1030     1040     1050     1060     1070     1080
MLV N417      TTACCCTGCTCTTACCCCTCTATAAAACCAGACCTTCTAAACCTCAGGTTCTCTCCGA
MTCR          TTACCCTGCTCTTACCCCTCTATAAAACCAGACCTTCTAAACCTCAGGTTCTCTCCGA
LAPC-4 (2010) TTACCCTGCTCTTACCCCTCTATAAAACCAGACCTTCTAAACCTCAGGTTCTCTCCGA
LAPC-4 (1998) TTACCCTGCTCTTACCCCTCTATAAAACCAGACCTTCTAAACCTCAGGTTCTCTCCGA
                    *****
Prim. cons.   TTACCCTGCTCTTACCCCTCTATAAAACCAGACCTTCTAAACCTCAGGTTCTCTCCGA

          1090     1100     1110     1120     1130     1140
MLV N417      TAATGGCGGACCTCTCATTGACCTTCTCACAGAAGACCTCCGCCGTACGGAGAACAGGG
MTCR          TAATGGCGGACCTCTCATTGACCTTCTCACAGAAGACCTCCGCCGTACGGAGAACAGGG
LAPC-4 (2010) TAATGGCGGACCTCTCATTGACCTTCTCACAGAAGACCTCCGCCGTACGGAGAACAGGG
LAPC-4 (1998) TAATGGCGGACCTCTCATTGACCTTCTCACAGAAGACCTCCGCCGTACGGAGAACAGGG
                    *****
Prim. cons.   TAATGGCGGACCTCTCATTGACCTTCTCACAGAAGACCTCCGCCGTACGGAGAACAGGG

          1150     1160     1170     1180     1190     1200
MLV N417      ACCGTCCTCCTCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC
MTCR          ACCGTCCTCCTCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC
LAPC-4 (2010) ACCGTCCTCCTCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC
LAPC-4 (1998) ACCGTCCTCCTCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC
                    *****
Prim. cons.   ACCGTCCTCCTCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC

          1210     1220     1230     1240     1250     1260
MLV N417      TGCCCCCTCTCCCATGGTGTCTCGCTTGCGGGGCAAAGAGACCCCCC-GCGGCAGTTT
MTCR          TGCCCCCTCTCCCATGGTGTCTCGCTTGCGGGGCAAAGAGACCCCCC-GCGGCAGTTT
LAPC-4 (2010) TGCCCCCTCTCCCATGGTGTCTCGCTTGCGGGGCAAAGAGACCCCCC-GCGGCAGTTT
LAPC-4 (1998) TGCCCCCTCTCCCATGGTGTCTCGCTTGCGGGGCAAAGAGACCCCCC-GCGGCAGTTT
                    *****
Prim. cons.   TGCCCCCTCTCCCATGGTGTCTCGCTTGCGGGGCAAAGAGACCCCCC-GCGGCAGTTT

          1270     1280     1290     1300     1310     1320
MLV N417      CCACCACCTCTCGGGCTTTCC-CACTCCGTTTGGGGGTAATGGTCAGTTGCAGTACTGG
MTCR          CCACCACCTCTCGGGCTTTCCGCACTCCGTTTGGGGGTAATGGTCAGTTGCAGTACTGG
LAPC-4 (2010) CCACCACCTCTCGGGCTTTCC-CACTCCGTTTGGGGGTAATGGTCAGTTGCAGTACTGG
LAPC-4 (1998) CCACCACCTCTCGGGCTTTCC-CACTCCGTTTGGGGGTAATGGTCAGTTGCAGTACTGG
                    *****
Prim. cons.   CCACCACCTCTCGGGCTTTCCGCACTCCGTTTGGGGGTAATGGTCAGTTGCAGTACTGG

          1330     1340     1350     1360     1370     1380
MLV N417      CCG-TTTTCCTCCTCGGATCTATATAACTGGAAAAATAAACCCTTCCTTCTCTGAAGA
MTCR          CCG-TTTTCCTCCTCGGATCTATATAACTGGAAAAATAAACCCTTCCTTCTCTGAAGA
LAPC-4 (2010) CCG-TTTTCCTCCTCGGATCTATATAACTGGAAAAATAAACCCTTCCTTCTCTGAAGA
LAPC-4 (1998) CCG-TTTTCCTCCTCGGATCTATATAACTGGAAAAATAAACCCTTCCTTCTCTGAAGA
                    *****
Prim. cons.   CCG-TTTTCCTCCTCGGATCTATATAACTGGAAAAATAAACCCTTCCTTCTCTGAAGA


```

Figure S7A. Early passage (1998) and late passage (2010) of LAPC-4 cells contain the same MLV sequences identical to MLV N417 strain at gag gene region. Representative sequencing data which were obtained by sequencing of XS3/XS4 PCR products of LAPC-4 DNA (see Sup. Table S3 for details). nt positions referred to MTCR (Accession no. X94150.1). MLV N417: GeneBank Accession no. HQ246218.

nt

```
5821          AATAGTTATA GGGATCTTGG TGAGGGCAGG AGCCTCGGTA
5881 CAACGTGACA GCCCTCACCA GGTCTTCAAT GTCACCTGGA GAGTTACCAA CCTAATGACA
5941 GGACAAACAG CTAACGCTAC CTCCTCTCTG GGGACGATGA CAGACACCTT CCCTAAACTA
6001 TATTTTGGACT TGTGTGATTT AGTTGGAGAC CATTGGGATG ACCCAGAACC CGATATTGGA
6061 GATGGTTGCC GCTCTCCGGG GGAAGAAAA AGGACAAGAC TGTATGACTT CTATGTTTGC
6121 CCCGGTCATA CTGTACCAAT AGGGTGTGGA GGGCCGGGAG AGGGCTACTG TGGCAAATGG
6181 GGATGTGAGA CCACTGGACA GGCATACTGG AAGCCATCAT CATCATGGGA CCTAATTTCC
6241 CTTAAGCGAG GAAACACTCC TAAGGATCAG GGCCCTGTG ATGATTCTCT GGTCTCCAGT
6301 GGCGTCCAGG GTGCCACACC GGGGGGTCTG TGCAACCCCC TAGTCTTAGA ATTCACTGAC
6361 GCGGGTAAAA AGGCCAGCTG GGATGCCCC AAAGTTTGGG GACTAAGACT CTACCGATCC
6421 ACGGGGGCCG ACCCGGTGAC CCGGTTCTCT TTGACCCGCC AGGTCTCTCA TGTAGGACCC
6481 CGCGTCCCCA TTGGGCCTAA TCCCGTGATC ACTGAACAGC TACCCCTCTC CCAACCCGTG
6541 CAGATCATGC TCCCCAGGCC TCCTCATCTT CCTCCTTTCAG GCGCGGCCTC TATGGTGCCT
6601 GGGGCTCCCC CGCCTTCTCA ACAACCTGGG ACGGGGGACA GGCTGCTAAA CCTAGTAAAA
6661 GGAGCCTATC AAGCACTCAA CCTCACCAGT CCCGACAGAA CCAAGAGTG CTGGCTGTGT
6721 CTGGTATCGG GACCCCTTA CTACGAAGGG GTTGCCGTCC TAGGTACCTA CTCCAACCAT
6781 ACCTCTGCCC CAGCTAACTG CTCCGTGGCC TCCCAACACA AGCTGACCCT GTCCGAAGTG
6841 ACCGGGCAGG GACTCTGCGT AGGAGCAGTT CCCAAAACCC ATCAGGCCCT GTGTAATACC
6901 ACCCAGAAGG CGAGCGACGG GTCCTACTAT CTGGCTGCTC CCGCCGGGAC CATCTGGGCT
6961 TGCAACACCG GGCTCACTCC CTGCCTATCT ACCACTGTAC TCAACCTCAC CACCGATTAC
7021 TGTGTCCTGG TTGAGCTCTG GCCAAAGGTG ACCTACCACT CCCCTGGTTA TGTTTATGAC
7081 CAGTTTGGAGA GAAAAACCAA ATATAAAGA GAGCCGGTGT CATTAACTCT GGCCCTGCTG
7141 TTGGGAGGAC
```

Figure S7B. LAPC-4 cells contain the MLV sequences of 100% homology to MLV N417 strain at env gene region. The LAPC-4 env gene sequencing data of nt 5840 to 7150 was obtained by sequencing XS14/XS15 PCR products of LAPC-4 DNA (early passage) (see Sup. Table S3 for details), and has 100% homology to MLV N417 strain. The nt positions referred to MLV N417: GeneBank Accession no. HQ246218.



1 2 3 4 5 6 7 8 9

Lane 1: LAPC-4 1998, XS3_XS4, gag PCR
 Lane 2: LAPC-4 2010, p138, XS3_XS4, gag PCR
 Lane 3: water only ctrl
 Lane 4: LAPC-4 1998, XS3_GagQ2R2, gag PCR
 Lane 5: LAPC-4 2010, p138, XS3_XS4, gag PCR
 Lane 6: water only ctrl
 Lane 7: LAPC-4 1998, GagQ2F2_XS4, gag PCR
 Lane 8: LAPC-4 2010, p138, GagQ2F2_XS4, gag PCR
 Lane 9: water only ctrl




Figure S7C. Detection of MLV-related sequences of different strains in LAPC-4 by three over-lapping PCR reactions and sequencing. The DNA of early or late passage of LAPC-4 cells (see Materials/Methods) were positively amplified with the products of approximate expected size by three sets of overlapping primers (XS3/XS4, XS3/GagQ2R2 and GagQ2F2/XS4) as illustrated (not up to the scale) in this figure. The PCR products were sequenced and analyzed (Sup. Figs. S7D and E).

```

          1030      1040      1050      1060      1070      1080
LAPC_4_XS3/XS4   TTACCCCTGCTCTTACCCCTCTATAAAACCCAGACCTTCTAAACCTCAGGTTCTCTCCGA
LAPC_4_GagQ2F2/XS4 -----CCCTCCGA
                                     * * * * *
Prim.cons.       TTACCCCTGCTCTTACCCCTCTATAAAACCCAGACCTTCTAAACCTCAGGTTCTCTCCGA

          1090      1100      1110      1120      1130      1140
LAPC_4_XS3/XS4   TAATGGCGGACCTCTCATTGACCTTCTCACAGAAGACCTCCGCCGTACGGGACAGGG
LAPC_4_GagQ2F2/XS4 --GCGGCGGCTCTC-----CGGCTCT-----GGCTCCCGCCGTACGGGACACA-----
                                     * * * * *
Prim.cons.       TA22GGCGG22CTCTCAT2G2CCT22TCACAGAAG2C2C2CCGCCGTACGGG2ACAGGG

          1150      1160      1170      1180      1190      1200
LAPC_4_XS3/XS4   ACCGTCCTCTCTGACGGAGATGGCGACAGAGAAGAGGCCACCTCCACTCCTGAGATTCC
LAPC_4_GagQ2F2/XS4 ACCTTCTCTCTGACGGAGAAACAATGAAAAGAGGCCGCCACCACCTCCGAGTTTC
                                     * * * * *
Prim.cons.       ACC2TCCTCTG2C2G2GA222C2A222A2AAGAGGC22CC2CCAC22C2GAG2TT2C

          1210      1220      1230      1240      1250      1260
LAPC_4_XS3/XS4   TGCCCCCTCTCCCATGGTGTCTCGCTTGGCGGGCAAAAGAGACCCCGCCGCGCAGTTTC
LAPC_4_GagQ2F2/XS4 CCCCCCTCTCCCATGGTGTCTCGACTGGCGGGAAGGAGAGACCTCCCGCAGCGACTC
                                     * * * * *
Prim.cons.       22CCCC2TCTCCCATGGTGTCTCG22TGGCGGG2A22AGAGACCC2CCCGC2GC2G22TC

          1270      1280      1290      1300      1310      1320
LAPC_4_XS3/XS4   CACCACCTCTCGGGCTTTCCCACTCCGTTGGGGGTAATGGTCAGTTCAGTACTGGCC
LAPC_4_GagQ2F2/XS4 CACCACCTCCAGGCGTTCCCACTCCGCA TGGGAGAAGATGGCCAGCTTCAGTACTGGCC
                                     * * * * *
Prim.cons.       CACCACCTC2C2GGC2TFTCCCACTCCG22TGGG2G222ATGG2CAG2T2CAGTACTGGCC

          1330      1340      1350      1360      1370      1380
LAPC_4_XS3/XS4   GTTTCTCTCTCGGATCTATATAACTGGAAAAATAATAACCCTTCCTTCTCTGAAGATCC
LAPC_4_GagQ2F2/XS4 GTTCTCTCTC-----CTTCCTTCTCTGAAGATCC
                                     * * * * *
Prim.cons.       GTT2TCCTCTCGGATCTATATAACTGGAAAAATAATAACCCTTCCTT2TCTGAAGATCC

          1390      1400      1410      1420      1430      1440
LAPC_4_XS3/XS4   AGGTAAATTGACTGCCTTAATCGAGTCTGTCTCACACCCACCAGCCTACTTGGGATGA
LAPC_4_GagQ2F2/XS4 AGGTAAATTGACGCCTTGATTGAGTCCGTCTCATCACCCACCAGCCACCCGGGACGA
                                     * * * * *
Prim.cons.       AGGTAAATTGAC2GCC2T2AT2GAGTCT2GTCTCA2CACCCACCAGCC2AC22GGGA2GA

          1450      1460      1470      1480      1490      1500
LAPC_4_XS3/XS4   CTGTCAACAGTTGCTGGGGACTCTGCTGACAGGAGAAGAAAAGCAGCGGGTGCTCCTGGA
LAPC_4_GagQ2F2/XS4 CTG-----
                                     * * *
Prim.cons.       CTGTCAACAGTTGCTGGGGACTCTGCTGACAGGAGAAGAAAAGCAGCGGGTGCTCCTGGA

```

Figure S7D. LAPC-4 cells contain 2 different MLV-related sequences at gag gene region. Alignment analysis of the sequencing data which were obtained by sequencing of XS3/XS4 or GagQ2F2/XS4 PCR products of LAPC-4 DNA (see Sup. Fig. S5A, Table S3 for details). nt positions referred to MLV N417 (GeneBank Accession no. HQ246218).


```

          1030      1040      1050      1060      1070      1080
          |         |         |         |         |         |
SP(B)1-2   GCGTCCCTCCGAGCGGCGGCTCTCCGGCCTCTGGCTCCCCGCCGTACGGAGCACAACTT
LAPC_4_GagQ2F2/XS4  ----CCCTCCGAGCGGCGGCTCTCCGGCCTCTGGCTCCCCGCCGTACGGAGCACAACTT
          *****
Prim.cons.  GCGTCCCTCCGAGCGGCGGCTCTCCGGCCTCTGGCTCCCCGCCGTACGGAGCACAACTT

          1090      1100      1110      1120      1130      1140
          |         |         |         |         |         |
SP(B)1-2   CCTCCTCTGCCAGGGAGAACAATGAAAAAGAGGCGGCCACCACCTCCGAGGTTTCCCCC
LAPC-4_GagQ2F2XS4  CCTCCTCTGCCAGGGAGAACAATGAAAAAGAGGCGGCCACCACCTCCGAGGTTTCCCCC
          *****
Prim.cons.  CCTCCTCTGCCAGGGAGAACAATGAAAAAGAGGCGGCCACCACCTCCGAGGTTTCCCCC

          1150      1160      1170      1180      1190      1200
          |         |         |         |         |         |
SP(B)1-2   CTTTCTCCCATGGTGTCTCGACTGCGGGGAAGGAGAGACCCTCCCGCAGCGGACTCCACCA
LAPC-4_GagQ2F2/XS4  CTTTCTCCCATGGTGTCTCGACTGCGGGGAAGGAGAGACCCTCCCGCAGCGGACTCCACCA
          *****
Prim.cons.  CTTTCTCCCATGGTGTCTCGACTGCGGGGAAGGAGAGACCCTCCCGCAGCGGACTCCACCA

          1210      1220      1230      1240      1250      1260
          |         |         |         |         |         |
SP(B)1-2   CCTCCCAGGCGTTCCCACTCCGCATGGGAGAAGATGGCCAGCTTCAGTACTGGCCGTCT
LAPC-4_GagQ2F2/XS4  CCTCCCAGGCGTTCCCACTCCGCATGGGAGAAGATGGCCAGCTTCAGTACTGGCCGTCT
          *****
Prim.cons.  CCTCCCAGGCGTTCCCACTCCGCATGGGAGAAGATGGCCAGCTTCAGTACTGGCCGTCT

          1270      1280      1290      1300      1310      1320
          |         |         |         |         |         |
SP(B)1-2   CCTCCCTTCCTTTTCTGAAGATCCAGGTAAATTGACGGCCTTGATTGAGTCCGTCCAT
LAPC-4_GagQ2F2/XS4  CCTCCCTTCCTTTTCTGAAGATCCAGGTAAATTGACGGCCTTGATTGAGTCCGTCCAT
          *****
Prim.cons.  CCTCCCTTCCTTTTCTGAAGATCCAGGTAAATTGACGGCCTTGATTGAGTCCGTCCAT

          1330      1340      1350      1360      1370      1380
          |         |         |         |         |         |
SP(B)1-2   CACCCACCAGCCACCCGGGACGACTGTCAGCAGTTGTTGGGGACCCTGCTGACCGGAGA
LAPC-4_GagQ2F2/XS4  CACCCACCAGCCACCCGGGACGACTG-----
          *****
Prim.cons.  CACCCACCAGCCACCCGGGACGACTGTCAGCAGTTGTTGGGGACCCTGCTGACCGGAGA

```

Figure S7E. LAPC-4 cells contain MLV-related sequences at gag gene region with 100 % homology to MLV SP(B) 1-2 isolate. The sequencing data which were obtained by sequencing of GagQ2F2/XS4 PCR products of LAPC-4 DNA (see Figs. S7A and B and Table S3 for details). nt positions referred to MLV SP(B) 1-2 (GeneBank Accession no. AY349140).




Figure S8. Validation of TM-PERT (Taqman fluorogenic 5'-nuclease Product-Enhanced Reverse Transcriptase) assay for measuring reverse transcriptase activity. See the Materials/Methods for the details. Titration range: $2 \times 10^5 \mu\text{U}/\text{rxn}$ to $0.02 \mu\text{U}/\text{rxn}$. Buffer or water only: completely negative here. Rxn: react

References for Supplementary Materials

1. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; 321:1801-6.
2. Brattain MG, Levine AE, Chakrabarty S, Yeoman LC, Willson JK, Long B. Heterogeneity of human colon carcinoma. *Cancer Metastasis Rev* 1984; 3:177-91.
3. Silverman RH, Nguyen C, Weight CJ, Klein EA. The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome. *Nat Rev Urol* 2010; 7:392-402.
4. Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J, et al. Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. *Retrovirology* 2009; 6:92.
5. McCormick AL, Brown RH, Jr., Cudkowicz ME, Al-Chalabi A, Garson JA. Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. *Neurology* 2008; 70:278-83.
6. Shi L, Chen Q, Norling LA, Lau AS, Krejci S, Xu Y. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification. *Biotechnol Bioeng* 2004; 87:884-96.
7. Johnson KL, Dukes KA, Vidaver J, LeShane ES, Ramirez I, et al. (2004) Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. *Clin Chem* 50: 516-521.
8. Brorson K, Xu Y, Swann PG, Hamilton E, Mustafa M, de Wit C, et al. Evaluation of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus in mAb cell-culture. *Biologicals* 2002; 30:15-26.
9. Brorson K, Swann PG, Lizzio E, Maudru T, Peden K, Stein KE. Use of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus levels in mAb cell-culture and downstream processing. *Biotechnol Prog* 2001; 17:188-96.
10. Peters SO, Bauermeister K, Simon JP, Branke B, Wagner T. Quantitative polymerase chain reaction-based assay with fluorogenic Y-chromosome specific probes to measure bone marrow chimerism in mice. *J Immunol Methods* 2002; 260:109-16.
11. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. *Cancer Res* 2004; 64:9027-34.